Purchase Order 75N91018P00294

The National Cancer Institute awarded a purchase order to Proteinsimple valued at $23,849.28 on July 25, 2018. No set-aside was used. Place of performance is Bethesda, Maryland. The order procures specialized protein analysis products, with an ultimate completion date of August 25, 2018. Proteinsimple is a for-profit manufacturer of advanced scientific equipment for biomedical research, including western blotting and capillary gel electrophoresis systems, and operates as a subsidiary of...

<p>The National Cancer Institute awarded a purchase order to Proteinsimple for $23,849.28 on January 17, 2019, with completion by February 18, 2019. The order is a firm fixed-price commercial item purchase with no set-aside designation. Performance occurs in San Jose, California. Proteinsimple manufactures specialized protein analysis equipment and associated services for biomedical research, including western blotting systems and capillary gel electrophoresis units.</p>

<p>The National Cancer Institute awarded a purchase order to Proteinsimple valued at $5,000.00 on March 29, 2016, for de-obligation of expiring FY2016 funds. Place of performance is Bethesda, Maryland. The order carries firm fixed pricing with an ultimate completion date of April 8, 2016.</p>

<p>The National Cancer Institute awarded a purchase order to ProteinSimple for a capillary-based nano-immunoassay, valued at $25,000, on August 9, 2017. Performance is located in Bethesda, Maryland, with an ultimate completion date of December 31, 2017. The order is priced on a firm fixed-price basis with no set-aside designation.</p>

<p>The National Cancer Institute issued a purchase order to Proteinsimple valued at $42,914.96 for reagents and assays for Peggy Sue instruments, awarded September 18, 2017, with completion by November 17, 2017. Place of performance is Bethesda, Maryland. The order is firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to ProteinSimple for training on ProteinSimple/Rigel Kishton technology, valued at $25,000.00, with an award date of August 16, 2017 and ultimate completion date of August 15, 2018. Place of performance is San Jose, California. The order is firm fixed price with no set-aside category.</p>

This federal contract award to Proteinsimple, also known as Bio-Techne Corporation Division, is for the provision of specialized protein analysis products and services to the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services (HHS). The contract, valued at $123,677.94, is for a firm-fixed-price purchase order to supply software and maintenance services for the SW0108 and SW0111 systems. The award has no set-aside designation and is effective from the...

<p>The National Institutes of Health Clinical Center awarded a purchase order to ProteinSimple for scanner equipment valued at $30,263.00 on May 11, 2021, with completion by June 10, 2021. The order is firm fixed price with no set-aside designation. Place of performance is San Jose, California, where ProteinSimple manufactures specialized protein analysis systems including western blotting and capillary electrophoresis platforms used across federal biomedical research agencies.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for $12,768.84 on September 11, 2018, with completion scheduled for September 18, 2019. Pricing is fixed-price with economic price adjustment. Place of performance is Bethesda, Maryland. The source does not identify the specific items or services procured under this order.</p>

This firm fixed-price purchase order, awarded by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, requires the contractor Proteinsimple (a division of Bio-Techne Corporation) to provide all labor, material, and equipment necessary to maintain two government-owned Peggy Sue capillary-based immunoassay instruments. The contract has a ceiling value of $103,601.43 and runs through August 31, 2024. No set-aside was used for this award....